An update from AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) is now available. AIM Vaccine Co., Ltd. has received approval from the National ...

There are two types of rabies vaccines: one is a serum-based rabies vaccine, and the other is a serum-free rabies vaccine. Currently, no serum-free rabies vaccine has been registered for market. The ...

On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announced that its self-developed mRNA shingles vaccine has recently been submitted for clinical approval to the U.S. Food and Drug ...

Aim Vaccine Co. Ltd. may become the first company to gain regulatory clearance of a prophylactic iterative serum-free human rabies vaccine. Beijing-based Aim said it is preparing a regulatory ...

As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine announced on February 26 that its self-developed mRNA RSV vaccine has recently received clinical trial ...

HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed ...

On-demand video webcast now availableIncludes latest updates on pancreatic cancer and bird flu clinical trialsOCALA, Fla., March 11, 2025 ...

HHS Secretary Robert F. Kennedy, Jr., suggests that 97% of the CDC's vaccine advisory committee members have conflicts of interests. His assertion inaccurately characterizes the report he cites.

On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announced that its self-developed mRNA shingles vaccine has recently been submitted for clinical approval to the U.S. Food and Drug ...